既往卒中对老年非瓣膜性心房颤动患者临床结局的影响:ANAFIE注册研究
有卒中/TIA病史者上述事件风险均更高;在既往缺血性卒中/TIA患者中,直接口服抗凝药组大出血、颅内出血和心血管死亡风险低于华法林组。
要点
- 年龄≥75岁非瓣膜性心房颤动患者中,22.6%有卒中/TIA病史。
- 有卒中/TIA病史者卒中/系统性栓塞风险为无病史者的2.25倍。
- 既往缺血性卒中/TIA患者中,直接口服抗凝药组大出血风险低于华法林组。
核心结论
- 年龄≥75岁非瓣膜性心房颤动且既往有卒中/TIA的患者,后续缺血性和出血性事件比无卒中/TIA病史者更常见。
- 在既往缺血性卒中/TIA患者中,服用直接口服抗凝药者出血事件风险低于服用华法林者。
研究设计与样本
- 前瞻性、多中心、观察性ANAFIE注册研究,纳入2016年10月至2018年1月期间年龄≥75岁、记录有非瓣膜性心房颤动的患者。
- 主要终点为2年内卒中/系统性栓塞,次要终点为2年内大出血和全因死亡,采用Cox模型比较风险。
主要发现
- 有卒中/TIA病史者较无病史者更可能为男性和高龄。
- 有卒中/TIA病史者卒中/系统性栓塞风险更高(校正风险比2.25[95%CI 1.97-2.58]),大出血风险更高(1.25[1.05-1.49]),全因死亡风险更高(1.13[1.02-1.24])。
- 6446例既往缺血性卒中/TIA患者中,4393例(68.2%)入组时服用直接口服抗凝药,1668例(25.9%)服用华法林。
- 直接口服抗凝药组与华法林组卒中/系统性栓塞风险相当(校正风险比0.90[95%CI 0.71-1.14]),直接口服抗凝药组大出血(0.67[0.48-0.94])、颅内出血(0.57[0.39-0.85])和心血管死亡(0.71[0.51-0.99])风险更低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We determined the long-term event incidence among elderly patients with nonvalvular atrial fibrillation in terms of history of stroke/transient ischemic attack (TIA) and oral anticoagulation. METHODS: Patients aged ≥75 years with documented nonvalvular atrial fibrillation enrolled in the prospective, multicenter, observational All Nippon Atrial Fibrillation in the Elderly Registry between October 2016 and January 2018 were divided into 2 groups according to history of stroke/TIA. The primary end point was the occurrence of stroke/systemic embolism within 2 years, and secondary end points were major bleeding and all-cause death within 2 years. Cox models were used to determine whether there was a difference in the hazard of each end point in patients with/without history of stroke/TIA, and in ischemic stroke/TIA survivors taking direct oral anticoagulants versus those taking warfarin. RESULTS: Of 32 275 evaluable patients (13 793 women [42.7%]; median age, 81.0 years), 7304 (22.6%) had a history of stroke/TIA. The patients with previous stroke/TIA were more likely to be male and older and had higher hazard rates of stroke/systemic embolism (adjusted hazard ratio, 2.25 [95% CI, 1.97-2.58]), major bleeding (1.25, 1.05-1.49), and all-cause death (1.13, 1.02-1.24) than the other groups. Of 6446 patients with prior ischemic stroke/TIA, 4393 (68.2%) were taking direct oral anticoagulants and 1668 (25.9%) were taking warfarin at enrollment. The risk of stroke/systemic embolism was comparable between these 2 groups (adjusted hazard ratio, 0.90 [95% CI, 0.71-1.14]), while the risk of major bleeding (0.67, 0.48-0.94), intracranial hemorrhage (0.57, 0.39-0.85), and cardiovascular death (0.71, 0.51-0.99) was lower among those taking direct oral anticoagulants. CONCLUSIONS: Patients aged ≥75 years with nonvalvular atrial fibrillation and previous stroke/TIA more commonly had subsequent ischemic and hemorrhagic events than those without previous stroke/TIA. Among patients with previous ischemic stroke/TIA, the risk of hemorrhagic events was lower in patients taking direct oral anticoagulants compared with warfarin. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique Identifier: UMIN000024006.
引用
- Yoshimoto T, Toyoda K, Ihara M, et al. Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry. Stroke. 2022. PMID: 35440169. doi:10.1161/STROKEAHA.121.038285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。